Patients with comorbid depression and insomnia do not feel satisfied by their health care providers or available treatment options.

CT-152 significantly outperformed sham control as an adjunct to ADT monotherapy in improving CGI-S and PHQ-9 scores among adults with MDD.

Early initiation of pimavanserin among patients with Parkinson disease psychosis were more likely to experience complete symptom resolution.

Esketamine for TRD demonstrated efficacy in reducing depressive symptoms and did not significantly differ based on TMS treatment history.

Over 30% of adults with ADHD treated with viloxazine ER experienced a 5% or greater sustained decrease in their baseline body weight.

Anhedonia in MDD was associated with high psychotropic medication use, health care utilization, and polypharmacy, as well as poor HRQoL.

High-dose centanafadine was well-tolerated and outperformed placebo in improving ADHD symptoms among children and adolescents with ADHD.

Relative to placebo, lumateperone significantly improved MADRS, CGI-S, and QIDS-SR-16 scores by day 43 among patients with MDD.

AXS-05 was associated with a significant and rapid reduction in AD agitation and was generally well tolerated across studies.

Pain interference had little effect on alcohol use days per month among AIAN adolescents with high levels of Tribal identity.

Those who receive the COVID-19 vaccine during pregnancy are less likely to be hospitalized for COVID-19; however, vaccine uptake in this population is suboptimal.

Exposure to maternal COVID-19 is not associated with abnormal neurodevelopmental screening results through 24 months postpartum.